SCHEMBL6359362

SCHEMBL6359362

CC(C)C(C(=O)O)N(CC(=O)c1ccccc1)C(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.42
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
USP2 O75604 1/20 0.41
MAPT P10636 3/20 0.40
HPGD P15428 3/20 0.40
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 2/20 0.40
MEN1 O00255 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
CES1 P23141 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
AGTR1 P30556 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 1/20 0.39
ADAMTS4 O75173 1/20 0.38
PGR P06401 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6358298 1.00 TSHR (0.42) TSHRALDH1A1KDM4EUSP2MAPT
SCHEMBL6357072 0.92 POLB (0.44) TSHRALDH1A1KDM4EUSP2MAPT
SCHEMBL6349879 0.92 ALDH1A1 (0.49) TSHRALDH1A1KDM4EUSP2HPGD
SCHEMBL6350477 0.89 L3MBTL1 (0.51) TSHRALDH1A1KDM4EMAPTHPGD
SCHEMBL6350864 0.88 TRPM8 (0.47) ALDH1A1KDM4EUSP2MAPTHPGD
SCHEMBL6359179 0.88 TRPM8 (0.47) ALDH1A1KDM4EUSP2MAPTHPGD
SCHEMBL6350978 0.88 ALDH1A1 (0.45) TSHRALDH1A1KDM4EUSP2MAPT
SCHEMBL6349361 0.88 ALDH1A1 (0.45) TSHRALDH1A1KDM4EUSP2MAPT
SCHEMBL6356051 0.88 ALDH1A1 (0.45) TSHRALDH1A1KDM4EUSP2MAPT
SCHEMBL6358289 0.87 ALDH1A1 (0.49) ALDH1A1MAPTKMT2ASMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 TSHR 338/4885ALDH1A1 420/4885KDM4E 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.